Cadrenal Therapeutics CEO presents at H.C. Wainwright Global Investment ConferencePUBT·14 hours agoCVKD-3.76%
U.S. stock market update: Cadrenal falls 16.57%, analysts maintain buy rating but market concerns persistPrice Alert·2 days ago, 02:48 PMCVKD-3.76%
12 Health Care Stocks Moving In Tuesday's Pre-Market Sessionbenzinga_article·2 days ago, 12:06 PMLABT-8.21%CLGN-0.61%
Regulatory Clarity and De-Risked Phase 3 Plan Support Cadrenal Buy Rating, $13 Target UnchangedTip Ranks·2 days ago, 10:25 AMCVKD-3.76%
12 Health Care Stocks Moving In Monday's Intraday Sessionbenzinga_article·Aug 31 at 05:06 PMAEMD+6.04%AIM-0.38%
Cadrenal Maintained at Buy as Partnership-Focused Strategy Supports Unchanged $13 Price TargetTip Ranks·Aug 14 at 10:26 AMCVKD-3.76%
Cadrenal Therapeutics Reports Second Quarter 2026 Financial Results; Provides a Corporate Update on the Cardiac Acute Critical Care Franchise and the Strategic Partnering ProcessUnusual Whales·Aug 13 at 08:17 PMCVKD-3.76%
Cadrenal Therapeutics highlights Phase 2 data for CAD-1005 in heparin-induced thrombocytopenia, eyes CSA-AKI marketPUBT·Aug 3 at 12:32 PMCVKD-3.76%
Cadrenal aligns pipeline into Cardiac Acute Critical Care Franchise, shifts to partnership-driven modelPUBT·Jul 21 at 12:06 PMCVKD-3.76%
Cadrenal's James J. Ferguson III to Resign as Chief Medical Officer, Separation Effective July 31, 2026TradingView·Jul 17 at 08:23 PMCVKD-3.76%
Cadrenal Therapeutics Reports Clinical Data From Phase 2 Study Of CAD-1005rttnews·Jul 13 at 01:52 PMCVKD-3.76%
